METAVIA INC. Business Combination, Consideration Transferred
METAVIA INC. (MTVA) reported Business Combination, Consideration Transferred of $17.72 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2022-03-31
- METAVIA INC. business combination, consideration transferred for fiscal 2021 was $17.72M, a 0.00% change from fiscal 2020.
- METAVIA INC. business combination, consideration transferred for fiscal 2020 was $17.72M.
| Period end | Business Combination, Consideration Transferred | Business Combination, Consideration Transferred 12 month |
|---|---|---|
| 2021-12-31 | $17.72M 10-K · filed 2022-03-31 | |
| 2020-12-31 | $17.72M 10-K · filed 2021-04-15 | |
| 2019-12-30 | $12.14M 10-K · filed 2021-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |